Key facts
- Standard Model Biomedicine’s last known valuation is $10.0M (Aug 2025).
- Notable investors include Virtue (Austin), Arkitekt Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Standard Model Biomedicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Standard Model Biomedicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Standard Model Biomedicine
Developer of artificial intelligence-based representations designed for biomedical modeling. The company's platform produces universal patient representations from any data modality, medical imaging, genomics, text, and pathology using state-of-the-art foundation models, enabling the biomedical research and clinical applications market to leverage predictive tools that unify diverse data and support robust outcome modeling.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2024
- Employees
- 6
- Website
- standardmodel.bio/
- Ownership
- Privately Held (backing)
Standard Model Biomedicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Standard Model Biomedicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Standard Model Biomedicine in its N-PORT filings yet. We sweep new filings monthly.